Technical Analysis for BEAM - Beam Therapeutics Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 21.55 | -2.44% | -0.54 |
BEAM closed down 2.44 percent on Friday, October 25, 2024, on 2.39 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
Earnings due: Nov 6
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
180 Bearish Setup | Bearish Swing Setup | 0.00% | |
Slingshot Bearish | Bearish Swing Setup | 0.00% | |
Stochastic Buy Signal | Bullish | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Hammer Candlestick | Bullish | -2.44% | |
Lizard Bullish | Bullish Day Trade Setup | -2.44% | |
Calm After Storm | Range Contraction | -2.44% | |
Doji - Bullish? | Reversal | -2.44% | |
Lower Bollinger Band Touch | Weakness | -2.44% | |
Oversold Stochastic | Weakness | -2.44% |
Alert | Time |
---|---|
Down 2 % | 2 days ago |
60 Minute Opening Range Breakdown | 2 days ago |
Possible NR7 | 2 days ago |
Up 1% | 2 days ago |
60 Minute Opening Range Breakout | 2 days ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/06/2024
Beam Therapeutics Inc., a biotechnology company, engages in developing precision genetic medicines for patients suffering from serious diseases in the United States. It is developing therapies for the development of sickle cell disease and beta-thalassemia; CAR-T cell therapies for pediatric T-cell acute lymphoblastic leukemia and pediatric acute myeloid leukemia; therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1A; and therapies for ocular and central nervous system disorders. The company was founded in 2017 and is based in Cambridge, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Gene Therapy Acute Myeloid Leukemia Leukemia Central Nervous System Disorders Nervous System Disorders Antitrypsin Deficiency Sickle Cell Disease Acute Leukemia Acute Lymphoblastic Leukemia Thalassemia Beta Thalassemia Glycogen Storage Disorder
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Gene Therapy Acute Myeloid Leukemia Leukemia Central Nervous System Disorders Nervous System Disorders Antitrypsin Deficiency Sickle Cell Disease Acute Leukemia Acute Lymphoblastic Leukemia Thalassemia Beta Thalassemia Glycogen Storage Disorder
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 49.5 |
52 Week Low | 18.18 |
Average Volume | 820,726 |
200-Day Moving Average | 26.82 |
50-Day Moving Average | 24.58 |
20-Day Moving Average | 23.73 |
10-Day Moving Average | 23.90 |
Average True Range | 1.22 |
RSI (14) | 36.31 |
ADX | 15.74 |
+DI | 18.82 |
-DI | 28.67 |
Chandelier Exit (Long, 3 ATRs) | 23.76 |
Chandelier Exit (Short, 3 ATRs) | 24.79 |
Upper Bollinger Bands | 26.55 |
Lower Bollinger Band | 20.90 |
Percent B (%b) | 0.11 |
BandWidth | 23.82 |
MACD Line | -0.65 |
MACD Signal Line | -0.35 |
MACD Histogram | -0.2988 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 22.78 | ||||
Resistance 3 (R3) | 22.90 | 22.61 | 22.58 | ||
Resistance 2 (R2) | 22.61 | 22.30 | 22.55 | 22.51 | |
Resistance 1 (R1) | 22.08 | 22.10 | 21.94 | 21.96 | 22.44 |
Pivot Point | 21.79 | 21.79 | 21.72 | 21.73 | 21.79 |
Support 1 (S1) | 21.26 | 21.48 | 21.12 | 21.14 | 20.66 |
Support 2 (S2) | 20.97 | 21.28 | 20.91 | 20.59 | |
Support 3 (S3) | 20.44 | 20.97 | 20.53 | ||
Support 4 (S4) | 20.32 |